Guide

Enclomiphene for low testosterone: what the trials show

It does what the lab report promises. Neither FDA nor the European regulator approved it, and a big reason is that nobody showed men actually feel better.

By Christian M, Certified Health Coach·

Key points

  • Enclomiphene is half of the fertility drug clomiphene, and it raises testosterone by making the body produce more of its own.
  • In 16-week phase 3 trials, it kept sperm counts in the normal range while testosterone gel pushed them down.
  • The trials measured hormone levels and sperm, not symptoms such as libido, impotence or bone strength; that gap, plus a blood clot risk, is why the EMA refused it in 2018.
  • No FDA-approved drug contains enclomiphene; it is made by compounding pharmacies, and FDA still lists it as under evaluation for that use.
  • Ask for LH and FSH testing and a monitoring plan before starting, and don't switch from prescribed testosterone on your own.

If you've been reading about low testosterone, you may have come across a daily pill described as a way to raise testosterone without shutting down sperm production. That pill is enclomiphene, which a 2026 case report describes as increasingly prescribed off-label. It has real trials behind it, and it does what it says on the lab report. It also has no approval in the United States or Europe, and the reasons behind that are worth knowing before you ask anyone to prescribe it.

What enclomiphene is

You may know its parent drug. Clomiphene, the active ingredient in an FDA-approved drug, is a mix of two geometric isomers (the same atoms arranged in two different shapes), enclomiphene and zuclomiphene. Based on the official clomiphene standard, between 50 and 70 percent of it is enclomiphene, according to an FDA review presented in 2022. Enclomiphene is that one half, sold on its own.

It works on the brain's hormone thermostat rather than replacing testosterone. Enclomiphene blocks estrogen receptors in the pituitary gland, which then releases more of the two hormones that tell the testes to work: LH (luteinizing hormone) and FSH (follicle-stimulating hormone). The testes respond by making more testosterone and more sperm, as the British Society for Sexual Medicine describes it.

That's the difference that sells it. Testosterone gels and injections switch that signal off, and the same statement notes that testosterone therapy typically suppresses sperm production within 3 to 6 months. One of the main trials put the idea in its title: restoration instead of replacement.

What the trials found

The early studies were small, and they came from the company developing the drug, Repros Therapeutics: the six-week trial lists Repros as its lead author's affiliation, and Repros holds the copyright on the sperm study described below. In a six-week trial, 44 men with low testosterone completed the protocol on 6.25, 12.5 or 25 mg of enclomiphene a day, or a testosterone gel. At six weeks, testosterone on the 25 mg dose averaged 604 ng/dL, against 500 ng/dL on the gel, a difference the authors found was not significant. LH and FSH went up on enclomiphene and down on the gel.

An early sperm result came from an even smaller study. Twelve men who had been using testosterone gel were switched, in an open-label trial, to either enclomiphene or the gel. Enclomiphene raised sperm counts in seven of seven men at 3 months and six of six at 6 months. One month after stopping, testosterone dropped back to where it started, which tells you it works only while you take it.

The largest evidence is a pair of phase 3 trials, ZA-304 and ZA-305, published in 2016. They were randomized, double-blind and placebo-controlled, and enrolled overweight men aged 18 to 60 with morning testosterone at or below 300 ng/dL and low or normal LH. After 16 weeks, testosterone rose in every treatment group. Sperm concentration stayed in the normal range on enclomiphene, while the testosterone gel group showed a marked reduction in sperm production.

A 2025 meta-analysis pooled 10 randomized trials with 819 men, combining clomiphene and enclomiphene. Compared with placebo, they raised total testosterone by about 274 ng/dL on average, with no significant difference from testosterone gel. Follow-up ran from 2 to 30 weeks, and the authors rated the evidence moderate quality. Across these trials, the rise in testosterone is the consistent part.

What nobody measured

A higher number on a lab report is not the same as feeling better. That gap is where enclomiphene's applications fell apart.

In January 2018 the European Medicines Agency recommended refusing a marketing authorization for enclomiphene, under the brand name EnCyzix. The company presented 4 main studies with 588 patients, measuring sperm and testosterone levels. The agency noted they did not look at whether the drug would improve symptoms such as bone strength, weight gain, impotence and libido. It also cited a risk of venous thromboembolism, blood clots in the veins, and concluded that the benefits did not outweigh the risks.

The American story is similar. An FDA physician told the agency's compounding committee in 2022 that Repros announced a complete response from FDA in 2015, saying the design of the phase 3 studies was not adequate to show clinical benefit. FDA's guidance for this condition says it is unclear whether raising testosterone in these men gives a clinical benefit, and that better semen results alone don't settle it, because improvement in semen parameters does not ensure fertility. The summary was blunt: the enclomiphene trials did not evaluate improvement in hypogonadal symptoms or quality of life.

That second point matters if fertility is your reason. The trials counted sperm. A sperm count is a reasonable sign, but it is not a pregnancy.

Side effects and safety questions

In the trial data the EMA reviewed, the most common side effects were headache, hot flushes, nausea and muscle spasms, as FDA's reviewer summarized it. The ones that led people to stop included blurred vision, muscle spasms, headache and aggression, and heart and clot events were slightly more common on enclomiphene than on testosterone. In a separate safety study, serious events included atrial flutter, pulmonary embolism and deep vein thrombosis. Cataracts appeared in animal studies. The EMA found no conclusive evidence that the drug causes them in people but wanted eye monitoring if it were approved.

FDA's reviewer listed the open safety questions as heart and clot events, raised estradiol, raised PSA and raised hematocrit (the share of blood made of red cells), with long-term data lacking.

Two later papers show how thin the evidence still is. The 2026 case report describes a 46-year-old man whose atrial flutter was first documented shortly after he took 50 mg a day by mistake instead of 25 mg. He had a heart valve repair 20 years earlier, and the authors say causality cannot be established. One case proves nothing, but it shows the kind of question nobody has data on yet. On the reassuring side, a 2024 review of 66 patients at a Texas academic clinic, men who had moved from clomiphene to enclomiphene, found fewer recorded side effects on enclomiphene. That was a look back at charts, not a trial, and the same men took both drugs in sequence.

Why you can still buy it

No FDA-approved drug contains enclomiphene, the FDA reviewer said in 2022. It can still be made by compounding pharmacies to fill an individual prescription and used off-label, as the BSSM statement notes. The developer stopped work on it in 2021, according to the same statement.

Whether compounding pharmacies may keep using it is still open. At the June 8, 2022 committee meeting, FDA proposed leaving enclomiphene off its list of substances allowed in this kind of compounding, and the committee voted 8 to 4 against adding it, with several members citing a lack of clinical efficacy evidence. Yet on FDA's nominations list updated May 14, 2026, enclomiphene citrate still sits in Category 1, "Bulk Drug Substances Under Evaluation". The final decision hasn't been made.

In the UK, the BSSM's 2026 position calls it promising but says use should be limited to clinicians experienced in male hypogonadism, ideally within research, because long-term safety and efficacy data are missing and it is unlicensed there. Three of its five authors list Menwell Limited (trading as Voy, Manual and H3 Health) among their affiliations; the paper declares no conflicts of interest.

Questions to ask before you start

None of this means enclomiphene is wrong for everyone. I'd want these answered by the person prescribing it before the first dose:

  • Ask which kind of low testosterone you have. The trials enrolled men whose low testosterone comes from the brain's signal (secondary hypogonadism), and the BSSM warns of limited success in some other types. That means LH and FSH should be measured, not only testosterone.
  • Ask whether keeping fertility is the real goal, since that is where the case for it is strongest.
  • Ask what will be checked and when: blood counts, PSA and estradiol were the open safety questions in FDA's review.
  • Mention any history of blood clots, heart rhythm problems, liver disease, or thyroid, adrenal or pituitary problems. The BSSM lists a history of liver disease, uncontrolled adrenal or thyroid dysfunction and certain pituitary conditions among its reasons not to use it.
  • Bring every bottle you take, including supplements such as tribulus, fadogia, ashwagandha or zinc.

If you're already on prescribed testosterone, don't switch on your own. That's a decision for the doctor managing it.

If you do start, Pilora can keep the daily dose on the same schedule as everything else you take.

The bottom line

Enclomiphene reliably raises testosterone, and in short trials it kept sperm counts where testosterone gel pushed them down. What hasn't been shown is that men feel better on it, or what years of use do, which is why neither FDA nor the EMA approved it. If preserving fertility is your reason, it's a fair question for a urologist or endocrinologist who checks LH and FSH first.

Related on Pilora

Sources

  1. Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone. BJU Int. 2016;117(4):677-85. BJU International, April 1, 2016.
  2. Wiehle RD et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial. Fertil Steril. 2014;102(3):720-7. Fertility and Sterility, September 1, 2014.
  3. Kaminetsky J et al. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone. J Sex Med. 2013;10(6):1628-35. Journal of Sexual Medicine, June 1, 2013.
  4. Wiehle R et al. Testosterone restoration by enclomiphene citrate in men with secondary hypogonadism: pharmacodynamics and pharmacokinetics. BJU Int. 2013;112(8):1188-200. BJU International, July 12, 2013.
  5. Hohl A et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Arch Endocrinol Metab. 2025;69(5):e250093. Archives of Endocrinology and Metabolism, October 9, 2025.
  6. Foster J et al. British Society of Sexual Medicine: position statement for the potential use of enclomiphene in the treatment of male hypogonadism. World J Mens Health. 2026;44(3):480-483. World Journal of Men's Health, February 13, 2026.
  7. Saffati G et al. Safety and efficacy of enclomiphene and clomiphene for hypogonadal men. Transl Androl Urol. 2024;13(9):1984-1990. Translational Andrology and Urology, September 30, 2024.
  8. Tariq MN et al. Newly detected atrial flutter after enclomiphene dose escalation: a case report. Cureus. 2026;18(8):e114562. Cureus, August 15, 2026.
  9. European Medicines Agency. Refusal of the marketing authorisation for EnCyzix (enclomifene), EMA/CHMP/54473/2018. European Medicines Agency, January 26, 2018.
  10. FDA Pharmacy Compounding Advisory Committee, meeting transcript, June 8, 2022 (FDA presentation on enclomiphene citrate). U.S. Food and Drug Administration, June 8, 2022.
  11. FDA Pharmacy Compounding Advisory Committee, final summary minutes, June 8, 2022. U.S. Food and Drug Administration, June 8, 2022.
  12. FDA. Bulk drug substances nominated for use in compounding under section 503A (updated May 14, 2026). U.S. Food and Drug Administration, May 14, 2026.

This article is general information, not medical advice. Do not start, stop or change a prescription medicine or its timing without your doctor or pharmacist. How we choose and check sources is explained on our methodology page.